Third-quarter performance2 buoyed by key growth drivers
Good performances from Lovenox® (+13.7%) and Lantus® (+21.7%) across all three
geographic regions, continuation of strong uptrend in the presence of Plavix® in the United States (+11.3%) and Japan (+50.3%)
Sales growth of 20.9% in emerging markets
Strong growth for the Pentacel® and Menactra® vaccines; substantial proportion of seasonal
and A/H1N1 vaccines sales anticipated in the fourth quarter
OTC sales up 26.3%
Launch of Multaq® in the United States on target; positive opinion from the CHMP in Europe, and approval in Canada and Switzerland
Impact of competition from generics of Eloxatin® in the United States and Plavix® in some European countries more than offset by growth drivers

Solid quarterly results and 2009 full-year guidance updated
2009 third-quarter adjusted EPS excluding selected items1 of €1.71, +8.2% at constant exchange rates and +16.3% on a reported basis
Robust cash flow from operating activities to end September, of €6,834 million
2009 guidance, taking account of approximately $500 million sales of A/H1N1 vaccines expected in the fourth quarter: growth in adjusted EPS excluding selected items1 of around 11% at constant exchange rates, barring major adverse events

Ongoing transformation of sanofi-aventis
Business Development: €6.2 billion invested to end September 2009
Reinforcement of the R&D portfolio: two projects (BSI-201 and otamixaban) moved into Phase III; two new alliances with Merrimack in oncology, and Wellstat in diabetes; agreement to acquire Fovea in ophthalmology
Expansion of the OTC business: agreement to acquire Oenobiol in France
Commenting on the Group’s 2009 third-quarter performance, sanofi-aventis Chief Executive Officer Christopher A. Viehbacher said:
“We pursued our transformation strategy in the third quarter, reinforcing our platforms for growth and forging ahead with our policy of R&D alliances and targeted acquisitions. As promised, we have mobilized substantial
resources on the production of A/H1N1 vaccines.”
(1) See Appendix 7 for definitions of financial indicators, and page 10 for details of selected items; (2) Growth in net sales is expressed at constant exchange rates unless otherwise indicated (see Appendix 7 for a definition).

2009 Guidance
Based on the good performance achieved over the first nine months of the year, and the expected contribution from approximately $500 million of H1N1 vaccine sales in the fourth quarter, sanofi-aventis has updated its
guidance for 2009 full-year growth in adjusted EPS excluding selected items1 of around 11%, calculated at constant exchange rates and barring major adverse events.